RAYMOND JAMES FINANCIAL INC
Position in LNTH — Lantheus Holdings, Inc.
CIK 720005
ST. PETERSBURG, FL
Position in LNTH
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$26,047,378
+$18,987,490 QoQ
Shares Held
234,788
+152.3% QoQ
Ownership
0.360%
of shares outstanding
% of Portfolio
0.01%
of 13F equity value
Holder Rank
#55
of 462 holders
Holding Since
Dec 2024
7 quarters on record
Voting authority
Sole 59%
Shared 0%
None 41%
Common Shares in LNTH Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - Specialty & Generic
Healthcare · as of Jun 30, 2026RAYMOND JAMES FINANCIAL INC holds $625,710,198 across 33 Drug Manufacturers - Specialty & Generic names. LNTH ranks #8 (4.2% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ZTS |
Zoetis Inc.
|
1,741,371 | $125,134,918 | |
| 2 | NBIX |
Neurocrine Biosciences Inc
|
580,170 | $97,781,849 | |
| 3 | HLN |
Haleon plc
|
7,278,875 | $67,911,902 | |
| 4 | ELAN |
Elanco Animal Health Inc
|
2,383,479 | $58,657,416 | |
| 5 | TEVA |
Teva Pharmaceutical Industries Ltd
|
1,692,660 | $57,347,317 | |
| 6 | UTHR |
UNITED THERAPEUTICS Corp
|
55,173 | $29,894,385 | |
| 7 | VTRS |
Viatris Inc
|
1,668,730 | $26,499,430 | |
| 8 | LNTH |
Lantheus Holdings, Inc.
This page
|
234,788 | $26,047,378 |
All Filings in LNTH
Export CSV
7 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $26,047,378 | 234,788 | Shares | Defined | 2026-08-14 | |
| 2026-03-31 | $7,059,888 | 93,077 | Shares | Defined | 2026-05-14 | |
| 2025-12-31 | $7,258,342 | 109,066 | Shares | Defined | 2026-02-18 | |
| 2025-09-30 | $5,814,593 | 113,367 | Shares | Defined | 2025-11-14 | |
| 2025-06-30 | $38,529,698 | 470,678 | Shares | Defined | 2025-08-14 | |
| 2025-03-31 | $36,733,319 | 376,366 | Shares | Defined | 2025-05-13 | |
| 2024-12-31 | $36,183,078 | 404,461 | Shares | Defined | 2025-04-23 | |
| No filing history on record for this holder in this stock. | ||||||